Quarterly ResultMay 11, 2026, 04:14 PM
Aktis Oncology Q1 Net Loss $18.3M; IPO Raises $334.4M
AI Summary
Aktis Oncology reported a net loss of $18.3 million for the three months ended March 31, 2026, an increase from $15.0 million in the prior year. The company successfully completed its initial public offering (IPO) in January 2026, raising approximately $334.4 million in net proceeds. This significant capital infusion dramatically improved the company's financial position, increasing cash and cash equivalents to $371.6 million and resulting in total stockholders' equity of $506.1 million.
Key Highlights
- Initial Public Offering (IPO) in January 2026 generated approximately $334.4 million in net proceeds.
- Net loss for Q1 2026 was $18.3 million, compared to $15.0 million for Q1 2025.
- Collaboration revenue increased to $3.2 million in Q1 2026 from $1.4 million in Q1 2025.
- Research and development expenses rose to $20.0 million in Q1 2026 from $15.9 million in Q1 2025.
- Cash and cash equivalents significantly increased to $371.6 million as of March 31, 2026, from $37.8 million at December 31, 2025.
- Total stockholders' equity reached $506.1 million as of March 31, 2026, reversing a $146.1 million deficit.
- Accumulated deficit as of March 31, 2026, was $174.9 million.